-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
Epstein-Barr virus (EBV)
Epstein-Barr virus (EBV) can invade host'B lymphocytes, T lymphocytes and NK cells for life. Antiviral drugs can specifically kill EBV-positive cells by reactivating the EBV lytic cycle, and studies have shown that histone deacetylase (HDAC) inhibitors can activate this kind of cycle. Among the HDAC inhibitors, vorinostat, romidepsin and chidamide are currently approved for the treatment of EBV.
As one of the most common human viruses, Epstein-Barr virus (EBV) is found all over the world. In general, EBV spreads most commonly through bodily fluids, primarily saliva. EBV can also cause infectious mononucleosis (IM), Burkitt's lymphoma (BL), nasopharyngeal carcinoma (NPC), Hodgkin's disease, and other diseases.
| CAS No. | Product Name | Inquiry |
|---|---|---|
| 254110-79-7 |
CEF27, Epstein-Barr Virus BRLF-1 lytic 148-156It is the 148-156 amino acid fragment of the BRLF1 protein. BRLF1 is a transcriptional activator that directly binds to GC-rich motif in the promoter of EBV lytic gene. |
※ Please kindly note that our services are for research use only.
